产品说明书
Bindarit
 |
同义名 : | AF2838;AF 2838 |
| CAS号 : | 130641-38-2 | |
| 货号 : | A189075 | |
| 分子式 : | C19H20N2O3 | |
| 纯度 : | 99% | |
| 分子量 : | 324.374 | |
| MDL号 : | MFCD00866723 | |
| 存储条件： |
粉末 Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 45 mg/mL(138.73 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
IP 2% DMSO+2% Tween80+40% PEG300+water 7 mg/mL clear PO 0.5% CMC-Na 38 mg/mL suspension |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Bindarit (AF2838) selectively inhibits monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, without affecting other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, and MIP-3/CCL23. It also exhibits anti-inflammatory properties[1]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01269242 | Coronary Restenosis | Phase 2 | Completed | - | Italy ... 展开 >> Fondazione S.Raffaele del Monte Tabor - UO Emodinamica e Cardiologia Interventistica Milan, Italy, 20132 收起 << |
| NCT01109212 | Diabetic Nephropathy | Phase 2 | Completed | - | Italy ... 展开 >> The Mario Negri Institute for Pharmacological Research- Clinical Research Center for Rare Diseases Ranica, Bergamo, Italy, 24020 Azienda Ospedaliera di Treviglio-Caravaggio - Unità Operativa Malattie Metaboliche e Diabetologia Treviglio, Bergamo, Italy, 24047 Azienda Ospedaliera OO.RR. Bergamo - Unità Operativa Diabetologia Bergamo, Italy, 24128 IRCCS Fondazione Centro S. Raffaele del Monte Tabor- Unità Operativa Medicina Generale Milano, Italy, 20132 Ist. Patologia Medica e metodologia Clinica - Università di Sassari Sassari, Italy, 7100 Slovenia University Medical Center Dpt Endocrinology Diabetes and Metabolic Diseases- Diabetology Unit Ljubljana, Slovenia, 1000 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.08mL 0.62mL 0.31mL |
15.41mL 3.08mL 1.54mL |
30.83mL 6.17mL 3.08mL |
| 参考文献 |
|---|